Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Alimentary Pharmacology & Therapeutics|October 28, 2020
Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North AmericaGolasa Samadi Kochaksaraei, Eliana Castillo, Matthew D Sadler, et al.
Journal of Hepatology|March 25, 2024
Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort studyChristina G Plagiannakos, Gideon M Hirschfield, Ellina Lytvyak, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Pageof 23